PRESS: FDA Fast Track, ODD, and RPDD Designations for FBX-101 Gene Therapy for Patients with Krabbe Disease

The FDA has granted Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation to FBX-101 for treatment of patients […]

Read More…

PRESS: FDA Clearance of Investigational New Drug for Patients with Krabbe Disease

Forge Biologics has received IND, IBC, and IRB clearance for FBX-101, a gene therapy for patients with Krabbe disease, a […]

Read More…